Published online Jan 16, 2024. doi: 10.4253/wjge.v16.i1.29
Peer-review started: October 6, 2023
First decision: December 6, 2023
Revised: December 7, 2023
Accepted: December 27, 2023
Article in press: December 27, 2023
Published online: January 16, 2024
Processing time: 100 Days and 21.6 Hours
Gastric variceal hemorrhage is one of the primary manifestations of left-sided portal hypertension (LSPH). The hemorrhage is fatal and requires safe and effective interventions.
To evaluate the clinical safety and efficacy of modified endoscopic ultrasound (EUS)-guided selective N-butyl-2-cyanoacrylate (NBC) injections for gastric variceal hemorrhage in LSPH.
A retrospective observational study of patients with LSPH-induced gastric variceal hemorrhage was conducted. Preoperative EUS evaluations were perfor
A total of 27 patients were enrolled. No statistically significant differences were observed between the two groups regarding baseline characteristics. In comparison to patients in the conventional group, patients in the modified group demonstrated significantly reduced NBC doses (2.0 ± 0.6 mL vs 3.1 ± 1.0 mL; P = 0.004) and increased endoscopic operation time (71.9 ± 11.9 min vs 22.5 ± 6.7 min; P < 0.001). Meanwhile, the two groups had no significant difference in the technical and clinical success rates, perioperative complications, postoperative hospital stay, and recurrent bleeding rates.
Modified EUS-guided selective NBC injections demonstrated safety and efficacy for LSPH-induced gastric variceal hemorrhage, with advantages of reduced injection dose and no radiation risk. Drawbacks were time consumption and technical challenge.
Core Tip: Gastric variceal hemorrhage is a severe and critical complication of left-sided portal hypertension (LSPH). Endoscopic ultrasound (EUS)-guided interventions are emerging endoscopic treatments with diagnostic and therapeutic potential. Our study revealed that EUS-guided selective N-butyl-2-cyanoacrylate injection is a safe and effective treatment alternative for patients with LSPH-induced gastric variceal hemorrhage, with reduced N-butyl-2-cyanoacrylate doses and satisfactory technical and clinical success rates.